WVE vs. URGN, AKBA, RAPT, MRNS, IDYA, DYN, PTCT, XENE, MLTX, and AGIO
Should you be buying Wave Life Sciences stock or one of its competitors? The main competitors of Wave Life Sciences include UroGen Pharma (URGN), Akebia Therapeutics (AKBA), RAPT Therapeutics (RAPT), Marinus Pharmaceuticals (MRNS), IDEAYA Biosciences (IDYA), Dyne Therapeutics (DYN), PTC Therapeutics (PTCT), Xenon Pharmaceuticals (XENE), MoonLake Immunotherapeutics (MLTX), and Agios Pharmaceuticals (AGIO). These companies are all part of the "pharmaceutical preparations" industry.
Wave Life Sciences (NASDAQ:WVE) and UroGen Pharma (NASDAQ:URGN) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, community ranking, valuation and media sentiment.
Wave Life Sciences has higher revenue and earnings than UroGen Pharma. Wave Life Sciences is trading at a lower price-to-earnings ratio than UroGen Pharma, indicating that it is currently the more affordable of the two stocks.
Wave Life Sciences has a beta of -1.03, meaning that its stock price is 203% less volatile than the S&P 500. Comparatively, UroGen Pharma has a beta of 1.08, meaning that its stock price is 8% more volatile than the S&P 500.
89.7% of Wave Life Sciences shares are owned by institutional investors. Comparatively, 91.3% of UroGen Pharma shares are owned by institutional investors. 31.1% of Wave Life Sciences shares are owned by insiders. Comparatively, 11.1% of UroGen Pharma shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Wave Life Sciences has a net margin of -54.61% compared to UroGen Pharma's net margin of -123.74%.
Wave Life Sciences presently has a consensus price target of $11.17, suggesting a potential upside of 92.20%. UroGen Pharma has a consensus price target of $46.00, suggesting a potential upside of 248.22%. Given UroGen Pharma's stronger consensus rating and higher possible upside, analysts clearly believe UroGen Pharma is more favorable than Wave Life Sciences.
In the previous week, UroGen Pharma had 2 more articles in the media than Wave Life Sciences. MarketBeat recorded 5 mentions for UroGen Pharma and 3 mentions for Wave Life Sciences. Wave Life Sciences' average media sentiment score of 1.06 beat UroGen Pharma's score of 0.00 indicating that Wave Life Sciences is being referred to more favorably in the media.
UroGen Pharma received 8 more outperform votes than Wave Life Sciences when rated by MarketBeat users. Likewise, 73.29% of users gave UroGen Pharma an outperform vote while only 67.18% of users gave Wave Life Sciences an outperform vote.
Summary
Wave Life Sciences beats UroGen Pharma on 9 of the 17 factors compared between the two stocks.
Get Wave Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for WVE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding WVE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Wave Life Sciences Competitors List
Related Companies and Tools
